Treatment of Endomyocardial Fibrosis: Heart Failure Medications and Device Implantation
Endomyocardial fibrosis is a restrictive cardiomyopathy characterised by progressive fibrotic involvement of the ventricular endocardium. Clinical management is driven by the severity of the resulting heart failure phenotype and the patient's symptom burden.
Treatment Approach
Management includes heart failure medications alongside consideration of device-based interventions — among them mechanical circulatory support as a bridge to further candidacy evaluation. The specific selection and sequencing of therapies depends on the individual's heart failure phenotype and severity.
The complete regimen — including full therapy selection, sequencing, and device criteria — is in the structured protocol below.
References
DOI: 10.1093/eurheartj/ehad194
The administration of heart failure medications and device implantation, including ventricular assist device as a bridge-to-candidacy is guided by symptoms and heart failure phenotype and severity, and is described in Section 6.10.2.
View source ↗